¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"minimal amplitude nystagmus"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • minimal bactericidal concentration
    ÃÖ¼Ò»ì±Õ³óµµ
  • minimal blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
  • minimal brain dysfunction
    °æ¹Ì³ú±â´ÉÀå¾Ö
  • minimal change disease
    ¹Ì¼¼º¯È­º´
  • minimal current gradient
    ÃÖ¼ÒÀü·ù±â¿ï±â, ÃÖ¼ÒÀü·ù°æ»ç
  • minimal effective analgesic concentration
    ÃÖ¼ÒÈ¿°úÁøÅë³óµµ
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • minimal erythema dose
    ÃÖ¼ÒÈ«¹Ý¼±·®
  • minimal identifiable odor
    ÃÖ¼ÒÀνij¿»õ, ÃÖ¼ÒºÐÇØÃë°¢
  • minimal infecting dose
    ÃÖ¼Ò°¨¿°¿ë·®
  • minimal inhibitory concentration
    ÃÖÀú¾ïÁ¦³óµµ
  • minimal lethal dose
    1. ÃÖ¼ÒÄ¡»ç·® 2. ÃÖ¼ÒÄ¡»ç¼±·®
  • minimal stimulus
    ÃÖ¼ÒÀÚ±Ø
  • minimal tension line
    ÃÖ¼ÒÀå·Â¼±
  • minimal visible angle
    Ãּҽð¢
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • minimal blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
  • minimal effective analgesic concentration
    ÃÖ¼ÒÈ¿°úÁøÅë³óµµ
  • minimal inhibitory concentration
    ÃÖÀú¾ïÁ¦³óµµ, ÃÖÀúÀúÁö³óµµ
  • minimal brain dysfunction
    °æ¹Ì³ú±â´ÉÀå¾Ö, ¹Ì¼Ò³ú±â´ÉÀå¾Ö
  • minimal change disease
    ÃÖ¼Òº¯È­ÄáÆÏº´Áõ
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • minimal erytherma dose
    ÃÖ¼ÒÈ«¹Ý¼±·®
  • minimal lethal dose
    ÃÖ¼ÒÄ¡»ç·®, ÃÖ¼ÒÄ¡»ç¼±·®
  • minimal enhancement
    ¹Ì¹ÌÇÑÁ¶¿µÁõ°­, °æµµÁ¶¿µÁõ°­
  • minimal current gradient
    ÃÖ¼ÒÀü·ù±â¿ï±â, ÃÖ¼ÒÀü·ù°æ»ç
  • minimal tension line
    ÃÖ¼ÒÀå·Â¼±
  • minimal stimulus
    ÃÖ¼ÒÀÚ±Ø
  • minimal angle resolution
    ÃÖ¼Ò°¢ºÐÇØ´É
  • minimal daily requirement
    ÃÖ¼Ò¿µ¾çÇʿ䷮, ÃÖ¼ÒÀÏÀϿ䱸·®
  • minimal identifiable odor
    ÃÖ¼ÒºÐÇØÃë°¢, ÃÖ¼ÒÀνij¿»õ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • after-nystagmus
    ÈĹ߾ÈÁø
  • alternating nystagmus
    ±³´ë¾ÈÁø (¡­äÑòè).
  • amaurotic nystagmus
    Èæ¾Ï½Ã¾ÈÁø
  • amblyopic nystagmus
    ¾à½Ã¾ÈÁø
  • galvanic nystagmus
    Àü±â¾ÈÁø(¡­äÑòè).
  • gaze nystagmus
    ÁֽþÈÁø
  • gaze nystagmus test
    ÁֽþÈÁø°Ë»ç
  • gaze paretic nystagmus
    Áֽø¶ºñ¾ÈÁø
  • gaze paretic nystagmus
    Áֽø¶ºñ¼º¾ÈÁø
  • head nystagmus
    ¸Ó¸®ÁøÅÁ(¡­òè.J), µÎÁø (Ôéòè).
  • head nystagmus
    ¸Ó¸® ÁøÅÁ(¡­òè.J), µÎÁø(Ôéòè)
  • head nystagmus
    µÎÁø
  • horizontal nystagmus
    ¼öÆò¾ÈÁø.
  • horizontal nystagmus
    ¼öÆò¾ÈÁø
  • hysterical nystagmus
    È÷½ºÅ׸®¾ÈÁø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • signal amplitude
    ½ÅÈ£ ÁøÆø
  • total amplitude
    ÃÑÁøÆø(õÅòÉøë), Ãѱ³Â÷, ÃÑÆí°¢.
  • minimal air
    ÃÖ¼Ò°ø±â.
  • minimal angle resolution
    ÃÖ¼Ò°¢ºÐÇØ´É.
  • minimal auditory threshold
    ÃÖ¼Ò°¡Ã»¿ªÄ¡(õÌ á³Ê¦ôéÚÊö·).
  • minimal auditory threshold
    ÃÖ¼Ò°¡Ã»¿ªÄ¡
  • minimal bactericidal concentration (MBC)
    »ì±ÕÃÖ¼Ò³óµµ
  • minimal blood pressure
    ÃÖ¼ÒÇ÷¾Ð.
  • minimal brain dysfunction
    °æ¹Ì³ú±â´ÉÀå¾Ö.
  • minimal brain dysfunction
    ¹Ì¼Ò³ú±â´ÉÀå¾Ö(Ú°á³ÒàѦÒöî¡äô)
  • minimal change disease
    ¹Ì¼Òº¯È­ »ç±¸Ã¼½Å¿°
  • minimal change disease
    ¹Ì¼Ò º´º¯½ÅÁõ(ڰܻ᳠ܨãìñø)
  • minimal current gradient
    ÃÖ¼ÒÀü·ù°æ»ç(¡­ï³êüÌËÞØ).
  • minimal current gradient
    ÃÖ¼ÒÀü·ù±¸¹è(¡­ï³êüÎþÛÕ).
  • minimal daily requirement
    ÃÖ¼Ò¿µ¾çÇʿ䷮(õÌá³ç½å×ù±é©åÖ), ÃÖ¼ÒÀÏÀϿ䱸·® .
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MIC maternal and infant care; medical intensive care; Medical Interfraternity Conference; microscopy; mi...
MPD main pancreatic duct; maximum permissible dose; mean population doubling; membrane potential differe...
AM Academic Medicine [journal]; actomyosin; acute myelofibrosis; adult male; adult monocyte; aerospace ...
am ametropia; amyl; amplitude; before noon [Lat. ante meridiem]; meter angle; myopic astigmatism
APA action potential amplitude; aldosterone-producing adenoma; Ambulatory Pediatric Association; America...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PR-N Postrotatory nystagmus
SN Spontaneous nystagmus
APA AP amplitude
APA Action potential amplitude
A Amplitude
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • aural nystagmus
    À̼º ¾ÈÁø
  • chene's nystagmus
    üÀÎ-½ºÅäÅ©½º ¾ÈÁø
  • circumduction nystagmus
    ¼øÈ¯ ¾ÈÁø
  • combined nystagmus
    º¹ÇÕ ¾ÈÁø
  • congenital nystagmus
    ¼±Ãµ¼º ¾ÈÁø
    ÁÖ½ÃÀÇ ¸ðµç À§Ä¡°¡ ¼öÆòÀÎ ÁøÀÚ¼º ¶Ç´Â À²µ¿¼º ¾ÈÁøÀ̸ç, ÆøÁÖ¿¡ ÀÇÇØ ¾àÈ­µÇ¸ç, ȯÀÚ´Â ¸Õ °Å¸®º¸´Ù °¡±î¿î °Å¸®¿¡¼­ ´õ Àß º»´Ù.
  • fixation nystagmus
    °í½Ã ¾ÈÁø
  • frequency of nystagmus
    ¾È ºóµµ
  • jerking nystagmus
    À²µ¿ ¾ÈÁø, À²µ¿¼º ¾ÈÁø
  • jerky nystagmus
    ¿îµ¿¼º ¾ÈÁø
  • monocular nystagmus
    ´Ü¾È ¾ÈÁø
  • nystagmus
    ¾ÈÁø, ¾È±¸ ÁøÅÁÁõ
  • ocular nystagmus
    ½Ã°¢¼º ¾ÈÁø, ½Ã°¢¼º ´« ¶³¸², ¾È¼º ¾ÈÁø, ½Ã¼º ¾ÈÁø
  • ocular optokinetic nystagmus
    ¾È±¸ ½Ã ¿îµ¿¼º ¾ÈÁø
  • optokinetic after nystagmus
    ½Ã ¿îµ¿ ÈÄ ¾ÈÁø, ½Ã ¿îµ¿¼º ÈÄ ¾ÈÁø
  • optokinetic nystagmus test
    ½Ã ¿îµ¿¼º ¾ÈÁø °Ë»ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
minimal dose <pharmacology> The smallest amount of a drug or physical procedure that will produce a desired physiologic effect in an adult.
(05 Mar 2000)
minimal infecting dose <microbiology> The smallest quantity of infectious material regularly producing infection; usually expressed as I.D.50, the quantity causing infection in 50% of a suitable series of animals or cells (cell cultures).
(05 Mar 2000)
minimal inhibitory concentration <microbiology, pharmacology> The lowest concentration of antibiotic sufficient to inhibit bacterial growth when tested in vitro.
(05 Mar 2000)
minimal lethal dose <pharmacology> The minimal dose of a toxic substance or infectious agent that is lethal, as assayed in various experimental animals (e.g., the least amount of diphtheria toxin that, on an average, kills a 250-g guinea pig within 96 hours after subcutaneous inoculation).
When followed by a subscript (generally "MLD50"), denotes the minimal dose that is lethal to a certain percentage (e.g., 50%) of animals so assayed, LD05.
See: lethal dose.
(05 Mar 2000)
minimal medium <cell culture> The simplest tissue culture medium that will support the proliferation of normal cells.
(18 Nov 1997)
minimal reacting dose The minimal dose of a toxic substance causing a reaction, as manifested in the skin of a series of susceptible test animals; the assay is based on the development of a characteristic, minimal but definite, "standard," focal inflammation (congestion and oedema, induration, degenerative changes, and desquamation of epidermal cells).
(05 Mar 2000)
after-nystagmus Nystagmus occurring after the abrupt cessation of rotation in the opposite direction of the rotatory nystagmus.
(05 Mar 2000)
amaurotic nystagmus The pendular or, rarely, jerky nystagmus seen in severely reduced vision.
Synonym: amaurotic nystagmus.
(05 Mar 2000)
Bruns' nystagmus A fine, jerking (vestibular) nystagmus on horizontal gaze in one direction, together with a slower, larger amplitude (gaze, paretic) nystagmus on looking in the opposite direction; due to lateral brainstem compression, usually by a cerebellar-pontine angle mass such as an acoustic neuroma.
(05 Mar 2000)
caloric nystagmus Jerky nystagmus induced by labyrinthine stimulation with warm or cold water injected into the ear canal.
(27 Sep 1997)
galvanic nystagmus Nystagmus involving galvanic stimulation of the labyrinth.
(05 Mar 2000)
palatal nystagmus A clonic spasm of the levator palati muscle, causing an audible click.
(05 Mar 2000)
railroad nystagmus Nystagmus induced by looking at moving visual stimuli.
Synonym: opticokinetic nystagmus, railroad nystagmus.
(05 Mar 2000)
gaze paretic nystagmus A nystagmus occurring in partial gaze paralysis when an attempt is made to look in the direction of the gaze paresis.
(05 Mar 2000)
vertical nystagmus An up-and-down oscillation of the eyes.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á